The Coalition for Epidemic Preparedness Innovations (CEPI) will be providing up to $19.3 million to support development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium consisting of Covaxin maker Bharat Biotech, the University of Sydney, and ExcellGene SA, Switzerland.
The funding will support the consortium as it seeks to establish pre-clinical and clinical proof of concept for an adjuvanted sub unit vaccine designed to provide broad protection against all known SARS-CoV-2 variants of concern, as well as future variants of the virus which have not yet emerged, CEPI said on Tuesday.
The researchers will get the funding to conduct activities, including immunogen design, preclinical studies, manufacturing process development and a Phase 1 clinical trial.